- |||||||||| Rituxan (rituximab) / Roche
Review, Journal: Ferroptosis mechanisms and its novel potential therapeutic targets for DLBCL. (Pubmed Central) - Mar 27, 2024
In this review, we elucidate ferroptosis mechanisms, its role in DLBCL, and the potential therapeutic targets in DLBCL. This review offers novel insights into the application of ferroptosis in treatment strategies for DLBCL.
- |||||||||| Rituxan (rituximab) / Roche
Journal: Primary adrenal lymphoma presenting as neurolymphomatosis: A case report. (Pubmed Central) - Mar 26, 2024
These findings support that their combination is a novel and promising therapeutic strategy for treating BC. Due to the nonspecific clinical presentation, patients with neurological damage should be alerted to the possibility of PAL and need to be evaluated thoroughly.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Lysine demethylase LSD1 is associated with stemness in EBV-positive B cell lymphoma. (Pubmed Central) - Mar 26, 2024
Here, we set out to identify an epigenetic regulator drug that acts synergistically with doxorubicin in EBV-positive lymphoma...We further observed that SOX2 expression was altered in response to CHAC2 expression, suggesting that stemness is regulated. Collectively, these findings suggest that LSD1 inhibitors could serve as promising therapeutic candidates for EBV-positive lymphoma, potentially reducing stemness activity when combined with conventional drugs to offer an effective treatment approach.
- |||||||||| sirolimus / Generic mfg.
Journal: Rapamycin increases leukemia cell sensitivity to chemotherapy by regulating mTORC1 pathway-mediated apoptosis and autophagy. (Pubmed Central) - Mar 26, 2024
In addition, western blot results demonstrated that rapamycin inhibited the phosphorylation of mTOR downstream targets 4EBP1 and S6K1 in SHI-1 cells, and increased the pro-apoptosis-related protein Bax and autophagy-associated proteins Beclin-1, LC3B-II, and ATG5 while reducing the anti-apoptosis-related protein Bcl-2. In conclusion, the results of this study indicate that rapamycin acts synergistically with doxorubicin and cytarabine in AML treatment, and its underlying mechanism might be associated with mTORC1 pathway-mediated apoptosis and autophagy.
- |||||||||| Epkinly (epcoritamab-bysp) / Genmab, AbbVie
Trial completion date, Adverse events, Combination therapy: EPCORE (clinicaltrials.gov) - Mar 25, 2024
P3, N=900, Recruiting,
In conclusion, both EGCG and RA effectively reduce Dox-induced genetic damage and enhance Dox's cell viability-reducing effect in breast cancer cells. Trial completion date: Sep 2037 --> May 2037
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Supramolecular self-assembled gold nanoparticle clusters for synergistic photothermal-chemo tumor therapy. (Pubmed Central) - Mar 25, 2024
Importantly, these hyaluronic acid modified AuNCs can shelter therapeutic cargo of doxorubicin (DOX) to aggregate larger nanoparticles via a host-guest interaction with the anchored ?-cyclodextrin, as a "nanocluster-bomb" (DOX@AuNCs)...The improved efficacy of synergistic therapy was further demonstrated by treating a xenografted B16 tumor model in vivo. We envision that our multipronged design of DOX@AuNCs provides a potent theranostic platform for precise cancer therapy and could be further enriched by introducing different imaging probes and therapeutic drugs as appropriate suitable guest molecules.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Albumin-ruthenium catalyst conjugate for bio-orthogonal uncaging of alloc group. (Pubmed Central) - Mar 25, 2024
Herein reported are the first preparation and demonstration of ruthenium catalysts with cyclopentadienyl and quinoline-based ligands conjugated to albumin. The effective uncaging abilities were demonstrated on allyloxy carbamate (alloc)-protected rhodamine 110 and doxorubicin, providing a promising catalytic scaffold for the advancement of selective drug delivery methods in the future.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Review, Journal: Ferroptosis mechanisms and regulations in cardiovascular diseases in the past, present, and future. (Pubmed Central) - Mar 25, 2024
As one of the cell death mechanisms, ferroptosis is a new form of regulated cell death (RCD) that broadly participates in CVDs (such as myocardial infarction, heart transplantation, atherosclerosis, heart failure, ischaemia/reperfusion (I/R) injury, atrial fibrillation, cardiomyopathy (radiation-induced cardiomyopathy, diabetes cardiomyopathy, sepsis-induced cardiac injury, doxorubicin-induced cardiac injury, iron overload cardiomyopathy, and hypertrophic cardiomyopathy), and pulmonary arterial hypertension), involving in iron regulation, metabolic mechanism and lipid peroxidation. This article reviews recent research on the mechanism and regulation of ferroptosis and its relationship with the occurrence and treatment of CVDs, aiming to provide new ideas and treatment targets for the clinical diagnosis and treatment of CVDs by clarifying the latest progress in CVDs research.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: SIRT6 activates PPAR? to improve doxorubicin-induced myocardial cell aging and damage. (Pubmed Central) - Mar 25, 2024
Echocardiography and HE staining revealed the restoration of cardiomyocyte alignment, affording protection against DOX-induced myocardial senescence and injury. The findings from this study suggest that SIRT6 holds significant promise as a therapeutic target for mitigating DOX-induced cardiomyopathy.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: microRNA-15a-5p suppresses hypoxia-induced tumor growth and chemoresistance in bladder cancer by binding to eIF5A2. (Pubmed Central) - Mar 24, 2024
However, the involvement of miRNAs in hypoxia-mediated bladder cancer doxorubicin (Dox) resistance is unknown...Collectively, these data indicated that hypoxia promotes tumor growth and chemoresistance through the HIF-1?/miR-15a-5p/eIFTA2/EMT pathway. This new finding not only has implications for improving our understanding of the Dox resistance process during bladder cancer progression but also indicates that the miR-15a-5p agomir is a promising tool to prevent Dox resistance in patients with bladder cancer.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Multifunctional Sr/Se co-doped ZIF-8 nanozyme for chemo/chemodynamic synergistic tumor therapy via apoptosis and ferroptosis. (Pubmed Central) - Mar 24, 2024
Consequently, improving the delivery of conventional chemotherapy drugs like doxorubicin (DOX) is crucial for their therapeutic efficacy...Additionally, the ZIF-8/SrSe@DOX nanoparticles efficiently delivered DOX, causing DNA damage and further promoting apoptotic and ferroptotic pathways. This research outlines the design of a novel platform that combines chemotherapeutic agents with a Fenton reaction catalyst, offering a promising strategy for cancer therapy that leverages the synergistic effects of apoptosis and ferroptosis.
- |||||||||| Epoch (epoetin beta biosimilar) / Roche, Rituxan (rituximab) / Roche
Journal, IO biomarker: High-grade B-cell lymphoma with a quadruple-hit genetic profile including concurrent MYC, BCL2, BCL6, and CCND1 gene rearrangements. (Pubmed Central) - Mar 24, 2024
Case 1 represented a 59-year-old female with widespread lymphadenopathy and a diagnosis of HGBL who exhibited primary refractoriness to dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) chemotherapy...Similarly, a literature review of 7 previously reported cases of HGBL with a quadruple-hit profile also demonstrated aggressive disease behavior. Our study adds 2 new cases to the rarely encountered quadruple-hit HGBL, and a brief meta-analysis of the 9 available cases indicates aggressive disease behavior conferred by this constellation of genetic events.
- |||||||||| rifampicin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
A Yellow Dialyzer () - Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_551;
Several substances have been attributed to discoloration including metabolites like bilirubin and drugs like doxorubicin and fluorescein dye. This case highlights the importance of observing the color of the dialyzer to assist in the diagnosis of certain disease states or drug exposures.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: A copper-loaded self-assembled nanoparticle for disturbing the tumor redox balance and triple anti-tumor therapy. (Pubmed Central) - Mar 22, 2024
stacking and hydrophobic interaction...Meanwhile, Cu2+-mediated GSH-consumption not only reduced the intracellular ROS elimination but also produced Cu+ to catalyze hydrogen peroxide (H2O2) and generated hydroxyl radicals (?OH), thereby enhancing the chemodynamic and photodynamic therapy. Herein, this study provides a green and relatively simple method for preparing multifunctional nanoparticles that can effectively modulate the TME and improve synergetic cancer therapy.
- |||||||||| doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg.
Journal, Metabolomic study: AI-assisted mass spectrometry imaging with in situ image segmentation for subcellular metabolomics analysis. (Pubmed Central) - Mar 22, 2024
Moreover, we identified that the downregulations of glutamate and aspartate in the malate-aspartate shuttle pathway may contribute to the higher paratoxicity of DOX. Our current AI-SMSI approach has promising applications for subcellular metabolomics analysis and thus opens new opportunities to further explore drug-cell specific interactions for the long-term pursuit of precision medicine.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: miR-218-5p and doxorubicin combination enhances anticancer activity in breast cancer cells through Parkin-dependent mitophagy inhibition. (Pubmed Central) - Mar 22, 2024
Afterwards, we demonstrated that the PINK1/Parkin-dependent mitophagy is indeed induced following DXR treatment and that exogenous expression of a small non-coding RNA, the miRNA-218-5p, known to target mRNA of Parkin, was sufficient to inhibit the DXR-mediated mitophagy in MCF7 and in MDA-MB-231 cells, thereby increasing their sensitivity to DXR. Considering the current challenges involved in BC refractory to treatment, our work could provide a promising approach to prevent tumour resistance and recurrence, potentially leading to the development of an innovative approach to combine mitophagy inhibition and chemotherapy.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: 5-Hydroxytryptophan acts as a gap junction inhibitor to limit the spread of chemotherapy-induced cardiomyocyte injury and mitochondrial dysfunction. (Pubmed Central) - Mar 22, 2024
Anthracycline chemotherapeutics like doxorubicin (DOX) are widely used against various cancers but are accompanied by severe cardiotoxic effects that can lead to heart failure...These findings shed light on the cardiotoxic mechanisms of DOX and suggest that 5-HTP could be a viable strategy to prevent heart damage during chemotherapy, offering a foundation for future clinical development. This research opens the door for 5-HTP to be considered a dual-purpose agent that can protect the heart without compromising the oncological efficacy of anthracycline chemotherapy.
- |||||||||| Kymriah (tisagenlecleucel-T) / Novartis, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Journal, CAR T-Cell Therapy, Real-world evidence, Real-world: Optimizing Real-World Outcomes in High-Risk Relapsed/Refractory (r/r) FL with CAR-T Cell Therapy: A Vodcast and Case Example. (Pubmed Central) - Mar 21, 2024
Not yet recruiting --> Recruiting | Initiation date: Sep 2023 --> Apr 2024 The patient received eight cycles of rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone (R-CHOP), followed by irradiation and rituximab maintenance (first-line) and then received rituximab 4?
- |||||||||| Epkinly (epcoritamab-bysp) / Genmab, AbbVie
Phase classification, Trial completion date, Trial primary completion date, Adverse events, Monotherapy: A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 21, 2024
P1, N=49, Active, not recruiting,
The patient received eight cycles of rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone (R-CHOP), followed by irradiation and rituximab maintenance (first-line) and then received rituximab 4? Phase classification: P1b/2 --> P1 | Trial completion date: Jan 2024 --> Dec 2024 | Trial primary completion date: Jan 2024 --> Dec 2024
- |||||||||| Brukinsa (zanubrutinib) / BeiGene, Rituxan (rituximab) / Roche
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy: Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Mar 21, 2024
P1, N=24, Recruiting,
Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 | Suspended --> Recruiting
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Functional Validation of Doxorubicin-Induced Cardiotoxicity-Related Genes. (Pubmed Central) - Mar 21, 2024
Furthermore, knockout of the uptake transporters (SLC28A3, SLC22A17, and SLC28A1) demonstrated a protective effect against DIC. The present findings establish a comprehensive platform for the functional validation of DIC-associated genes, providing insights for future studies in DIC variant associations and potential mechanistic targets for the development of cardioprotective drugs.
- |||||||||| Polivy (polatuzumab vedotin-piiq) / Roche, Rituxan (rituximab) / Roche
Trial completion date, Trial primary completion date, Combination therapy: Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma (clinicaltrials.gov) - Mar 21, 2024
P2, N=49, Recruiting,
Our study comprehensively explored the role of PANoptosis-related molecule CASP2 in HCC, which can provide directions for future studies. Trial completion date: Nov 2023 --> Nov 2026 | Trial primary completion date: Nov 2023 --> Nov 2025
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Preclinical, Journal: Evaluation of mAb 2C5-modified dendrimer-based micelles for the co-delivery of siRNA and chemotherapeutic drug in xenograft mice model. (Pubmed Central) - Mar 20, 2024
In this study, monoclonal antibody 2C5-modified dendrimer-based micelles were used to co-deliver siRNA and doxorubicin (DOX) to the tumor site in both male and female xenograft mouse model...We observed a 29% reduction of P-gp levels in both males and females with respect to the control (BHG). We also conclude that the dose of DOX and siRNA should be further optimized to have a better efficacy in a metastatic tumor model, which will be the subject of our future studies.
|
